Immunophenotypic stability of Sézary cells by flow cytometry usefulness of flow cytometry in assessing response to and guiding alemtuzumab therapy

James Vaughan, Alexandra M. Harrington, Parameswaran N. Hari, Steven H. Kroft, Horatiu Olteanu

Research output: Contribution to journalArticle

16 Scopus citations

Abstract

Flow cytometry (FC) is frequently used to detect aberrant peripheral blood (PB) T cells ("Sézary cells") in patients with mycosis fungoides (MF) and Sézary syndrome (SS). However, immunophenotypic stability of MF/SS over time is not well characterized. We analyzed 141 PB samples from 9 cases (2 SS, 7 MF). At diagnosis, there were 3 to 5 immunophenotypic aberrancies per case (median, 4), including dim or absent CD2, CD3, CD4, CD5, CD7, or CD26 and bright CD45RO. Of 9 patients, 7 had a subsequent change in immunophenotype. All patients retained multiple aberrancies at follow-up (median, 3 per analysis; range, 2-6), of which 22.0% (81/369) were new. In 5 patients, a more than 99% decrease in absolute Sézary cell (ASC) counts by FC after alemtuzumab therapy or total skin electron beam radiation was associated with clinical improvement. We observed minor immunophenotypic changes over time in most patients with MF/SS; however, the Sézary clones maintain persistently aberrant immunophenotypes and seem amenable to follow-up with limited FC panels. ASC counts by FC correlated well with clinical response. Copyright

Original languageEnglish (US)
Pages (from-to)403-411
Number of pages9
JournalAmerican journal of clinical pathology
Volume137
Issue number3
DOIs
StatePublished - Mar 1 2012

Keywords

  • Alemtuzumab
  • Flow cytometry
  • Immunophenotype
  • Sézary

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Fingerprint Dive into the research topics of 'Immunophenotypic stability of Sézary cells by flow cytometry usefulness of flow cytometry in assessing response to and guiding alemtuzumab therapy'. Together they form a unique fingerprint.

  • Cite this